Clopidogrel Hyper-Response and Bleeding Risk in Neurointerventional Procedures

References

1. 1.↵
   1. Bhatt DL,
   2. Kapadia SR,
   3. Bajzer CT,
   4. et al

   . Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. J Invasive Cardiol 2001;13:767–71

   PubMed
2. 2.↵
   1. Cohen M

   . Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Catheter Cardiovasc Interv 2009;74:579–97

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Snoep JD,
   2. Hovens MM,
   3. Eikenboom JC,
   4. et al

   . Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221–31

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Musallam KM,
   2. Charafeddine K,
   3. Bitar A,
   4. et al

   . Resistance to aspirin and clopidogrel therapy. Int J Lab Hematol 2011:33:1–18

   PubMed
5. 5.↵
   1. Scott SA,
   2. Sangkuhl K,
   3. Gardner EE,
   4. et al

   . Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clin Pharmacol Ther 2011;90:328–32

   CrossRefPubMed
6. 6.↵
   1. Ari H,
   2. Ozkan H,
   3. Karacinar A,
   4. et al

   . The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (The EFFICIENT Trial). Int J Cardiol 2012;157:374–80

   CrossRefPubMed
7. 7.↵
   1. Campo G,
   2. Fileti L,
   3. de Cesare N,
   4. et al

   . Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention. J Am Coll Cardiol 2010;56:1447–55

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Price MJ,
   2. Endemann S,
   3. Gollapudi RR,
   4. et al

   . Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992–1000

   Abstract/FREE Full Text
9. 9.↵
   1. Aradi D,
   2. Komócsi A,
   3. Vorobcsuk A,
   4. et al

   . Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010;160:543–51

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Holmes DR,
    2. Dehmer GJ,
    3. Kaul S,
    4. et al

    . ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”—a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010;122:537–57

    FREE Full Text
11. 11.↵
    1. Sibbing D,
    2. Schultz S,
    3. Braun S,
    4. et al

    . Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250–56

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Cuisset T,
    2. Cayla G,
    3. Frere C,
    4. et al

    . Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome: shifting from antiplatelet resistance to bleeding risk assessment? Eurointervention 2009;5:325–29

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Serebruany V,
    2. Rao SV,
    3. Silva MA,
    4. et al

    . Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010;31:227–35

    Abstract/FREE Full Text
14. 14.↵
    1. van Werkum JW,
    2. Harmsze AM,
    3. Elsenberg EH,
    4. et al

    . The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets 2008;19:479–88

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Varenhorst C,
    2. James S,
    3. Erlinge D,
    4. et al

    . Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 2009;157:562.e1–e9

    CrossRefPubMed
16. 16.↵
    1. Cuisset T,
    2. Frere C,
    3. Poyet R,
    4. et al

    . Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch Cardiovasc Dis 2010;103:39–45

    CrossRefPubMed
17. 17.↵
    1. Breet NJ,
    2. van Werkum JW,
    3. Bouman HJ,
    4. et al

    . Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754–62

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Ryu DS,
    2. Hong C-K,
    3. Sim YS,
    4. et al

    . Anti-platelet drug resistance in the prediction of thromboembolic complications after neurointervention. J Korean Neurosurg Soc 2010;48:319–24

    CrossRefPubMed
19. 19.↵
    1. Müller-Schunk S,
    2. Linn J,
    3. Peters N,
    4. et al

    . Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting. AJNR Am J Neuroradiol 2008;29:786–91

    Abstract/FREE Full Text
20. 20.↵
    1. Prabhakaran S,
    2. Wells KR,
    3. Lee VH,
    4. et al

    . Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281–85

    Abstract/FREE Full Text
21. 21.↵
    1. Lee DH,
    2. Arat A,
    3. Morsi H,
    4. et al

    . Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am J Neuroradiol 2008;29:1389–94

    Abstract/FREE Full Text
22. 22.↵
    1. Byrne JV,
    2. Beltechi R,
    3. Yarnold JA,
    4. et al

    . Early experience in the treatment of intra-cranial aneurysms by endovascular flow diversion: a multicentre prospective study. PLoS One 2010;5. pii: e12492
23. 23.↵
    1. Nelson PK,
    2. Lylyk P,
    3. Szikora I,
    4. et al

    . The Pipeline embolization device for the intracranial treatment of aneurysms trial. AJNR Am J Neuroradiol 2011;32:34–40

    Abstract/FREE Full Text
24. 24.↵
    1. Bauer T,
    2. Bouman HJ,
    3. van Werkum JW,
    4. et al

    . Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011:343:d4588

    Abstract/FREE Full Text
25. 25.↵
    1. Tiroch KA,
    2. Sibbing D,
    3. Koch W,
    4. et al

    . Protective effect of the CYP2C19 17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010;160:506–12

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Sibbing D,
    2. Koch W,
    3. Gebhard D,
    4. et al

    . Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010;121:512–18

    Abstract/FREE Full Text
27. 27.↵
    1. Sibbing D,
    2. Gebhard D,
    3. Koch W,
    4. et al

    . Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost 2010;8:1685–93

    CrossRefPubMedWeb of Science